Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 30, 2026

Beeline Reports 127% Revenue Growth and Improved Loan Economics

View original at globenewswire.com
Beeline Reports 127% Revenue Growth and Improved Loan Economics Revenue growth expected to accelerate in 2026 Management to host conference call today at 5 p.m…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In 2025, Beeline became a public company, strengthened balance sheet by eliminating debt, and built technology stack

    60% confidence

  • BeelineEquity offering is a differentiated solution to tap into the $4 trillion in illiquid home equity

    60% confidence

  • BeelineEquity launch gives greater confidence in growth and margin trajectory moving through the year

    60% confidence

  • Company has a clear and increasingly diversified pathway to achieving $100 million run rate over the next couple of years

    60% confidence

  • Beeline is positioned at the intersection of three large and growing markets: digital mortgage origination, AI-driven financial infrastructure, and fractionalized real estate ownership

    60% confidence

  • Company has built a platform that can scale significantly without meaningful incremental costs

    60% confidence

  • Higher average revenue per loan and lower expenses per loan are supporting progress towards cash flow break-even

    60% confidence

  • Company is poised for accelerated growth while continuing to improve loan-level economics

    60% confidence

  • Revenue growth expected to accelerate in 2026

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com